Kibion

Kibion

Uppsala, Germany· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Kibion is a global leader in the Helicobacter pylori diagnostics market, offering a vertically integrated solution that combines proprietary UBT kits with specialized IRIS™ breath analysis instruments. Founded in 2005 as a subsidiary of Orexo AB, the company transformed through the acquisition of Wagner Analysen Technik GmbH in 2011 and was later acquired by Mayoly Spindler in 2016, solidifying its position within a larger healthcare group. Its business model is focused on diagnostics, with a commercial-stage product portfolio sold in over 50 countries, targeting hospitals, laboratories, and clinics.

GastroenterologyInfectious Diseases

Technology Platform

Integrated Urea Breath Test (UBT) system utilizing 13C-labeled urea and proprietary IRIS™ infrared spectroscopy instruments for non-invasive detection of Helicobacter pylori.

Opportunities

Growth is driven by the high global prevalence of H.
pylori and clinical guidelines favoring non-invasive UBT as the diagnostic gold standard.
Integration with Mayoly Spindler's gastroenterology-focused commercial network provides significant cross-selling and market expansion potential.

Risk Factors

The business is concentrated on a single diagnostic application, creating vulnerability to market shifts.
Competition from alternative diagnostic methods (stool antigen, serology) presents a constant challenge.
As a subsidiary, strategic direction depends on the parent company's priorities.

Competitive Landscape

Kibion competes in the H. pylori diagnostics market against other UBT kit manufacturers, stool antigen test providers, and serology assays. Its key competitive advantage is its vertically integrated 'complete solution' of kits and proprietary analyzers, targeting the laboratory and hospital segment for high accuracy and throughput.